Where Sjögren's disease treatment is heading
Sjögren's disease · Updated Nov 13, 2026
Sjögren's disease is an autoimmune condition that attacks the glands that make tears and saliva, causing dry eyes and mouth, fatigue and joint pain; some people have organ involvement. It mostly affects women. No drug is approved to treat the disease itself, but several reached positive phase 3 results in 2025–2026.
- 39studies open or running
- 2phase 3 trials
- 1,290papers published this year
- 5NIH-funded projects
-
Now
Nov 2026
First phase 3 successesHappened
Ianalumab succeeded in two phase 3 trials and received Breakthrough Therapy designation.
Dazodalibep also positiveHappened
OASIZ-301 lowered disease activity, and the monthly dose improved dryness.
Lymphoma risk is realHappened 8.78× lymphoma risk
Non-Hodgkin lymphoma is about 8.78 times as common in Sjögren's.
8.78×: risk of non-Hodgkin lymphoma.
-
6 months
by May 2027
Second dazodalibep trial and deucravacitinibLikely
OASIZ-303 and the 774-person POETYK SjS-1 trial of deucravacitinib both finish late 2026.
-
12 months
by Nov 2027
First approved Sjögren's drugPossible
Ianalumab is under regulatory review and is the likeliest first approval.
-
3 years
by late 2029
Antibody-clearing drugsPossible 163 people in phase 2
Nipocalimab helped in phase 2; Immunovant is testing IMVT-1402 in 180 people.
163: people in the trial.
-
5 years
by late 2031
Cell therapies to reset the immune systemLong shot
Early trials test donor NK cells and CAR T cells for severe Sjögren's.
The research paths
B-cell and immune-signal drugs
Details and 1 trialsHide
Ianalumab and dazodalibep target B cells and the signals that activate them.
WatchApproval decisions.
Antibody-clearing (FcRn) drugs
163 people in phase 2Details and 1 trialsHide
Lowering harmful IgG antibodies.
WatchIMVT-1402 results.
Cell therapy and pills
Details and 2 trialsHide
NK cells, CAR T cells and JAK pills.
WatchSafety data.
Borrowed from other conditions
From Myasthenia gravis
Nipocalimab
Phase 2 positive
An FcRn blocker approved for myasthenia gravis.
From Psoriasis
Deucravacitinib
Phase 3
A TYK2-blocking pill approved for psoriasis.
Open to join now
-
Active disease
AlloNK cell therapy
Locations and eligibility → -
NIH Clinical Center
Tofacitinib
Locations and eligibility →
See every recruiting Sjögren's trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Dazodalibep phase 3 positive
OASIZ-301.
Nipocalimab lowers disease activity
The Lancet, phase 2.
Standard treatment today
- DrynessArtificial tears, cyclosporine or lifitegrast eye drops; saliva substitutes; pilocarpine or cevimeline.
- Joint pain and fatigueHydroxychloroquine; exercise.
- Organ involvementSteroids, methotrexate, mycophenolate or rituximab, chosen by organ.
How to read this page, and sourcesHow to read this page, and sources
- Most trials measure systemic disease activity; dryness and fatigue are harder to improve.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Sjögren's trials recruiting now →